The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Start Date09 Feb 2026

Sponsor / Collaborator

University of Miami

[+1]

NCT07218796

/ RecruitingPhase 3

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Start Date28 Oct 2025

Sponsor / Collaborator

SpyGlass Pharma, Inc.

NCT07218783

/ RecruitingPhase 3

Start Date15 Oct 2025

Sponsor / Collaborator

SpyGlass Pharma, Inc.

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

1,057

Literatures (Medical) associated with Bimatoprost

01 Feb 2026·DRUGS & AGING

Implants to Treat Glaucoma: Promising or Not?

Review

Author: Kolko, Miriam ; Cvenkel, Barbara

Glaucoma is one of the leading causes of blindness and its prevalence increases with age. The most common form, primary open-angle glaucoma, is a chronic, slowly progressive optic neuropathy characterised by the loss of retinal ganglion cells and their axons, leading to irreversible visual field loss. Elevated intraocular pressure (IOP) is the only modifiable risk factor for glaucoma. Reducing IOP to a level that is safe for the patient's eye has been shown to slow disease progression. Lowering IOP in open-angle glaucoma is achieved by eye drops, selective laser trabeculoplasty (SLT) and/or surgery. Many patients are treated with IOP-lowering eye drops, which require lifelong continuous instillation. However, as with other chronic, asymptomatic diseases, adherence to glaucoma treatment is poor for various reasons and is associated with faster disease progression. The purpose of this review is to discuss several sustained-release systems that have been investigated to reduce IOP over time, to address barriers to adherence and improve quality of life. Among these, non-invasive drug-eluting delivery systems such as contact lenses, punctal plugs, and conjunctival ocular inserts have not reached the market. Currently, only two intracameral implants have been approved by the Food and Drug Administration for single use due to corneal safety issues. The biodegradable bimatoprost implant releases the drug continuously for 4-6 months, and its effect on IOP may extend for up to 2 years in 25% of patients. The non-biodegradable intracameral implant releases travoprost for 36 months, when it needs to be removed. However, additional data are needed to assess safety following repeated administration, as well as in broader patient populations and in combination with other treatment approaches such as SLT. Several other biodegradable intracameral implants that release prostaglandin analogues are undergoing clinical trials. In the future, intraocular implants containing genetically modified cells that secrete neurotrophic factors may potentially offer an IOP-independent neuroprotective strategy, complementing existing IOP-lowering implants in glaucoma management.

01 Feb 2026·Ophthalmology and Therapy

Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results

Article

Author: Gupta, Preeya K ; Kahook, Malik Y ; Katz, Gregory ; Sussman, Glenn ; Radcliffe, Nathan M ; Tan, Nicholas E ; Robles, Marco ; Yoo, Paul

INTRODUCTION:

This study aimed to explore the safety and efficacy of sustained release bimatoprost implant with SpyGlass intraocular lens (SpyGlass Pharma, Inc., Aliso Viejo, CA, USA).

METHODS:

Twenty-four subjects diagnosed with cataracts and mild-to-moderate primary open-angle glaucoma were consented at a single site in Honduras. Those with pathologies that could confound outcomes were excluded. All subjects were required to have responded to topical prostaglandin analogues. Medication washout was performed prior to intervention. One eye of each subject was sequentially assigned to one of three arms (75 μg, 150 μg, or 300 μg of bimatoprost pads). The product was delivered in-the-bag via a commercially available intraocular lens (IOL) inserter and did not modify the steps of standard phacoemulsification cataract surgery other than attachment of bimatoprost implants to the IOL. We report interim results through 36 months.

RESULTS:

Twenty-one of 24 enrollees (87.5%) were retained through 36 months. Through 24 months, all subjects achieved the primary endpoint of intraocular pressure (IOP) reduction > 20% from baseline without any additional glaucoma medications. By month 36, all but a single subject (95.2%, n = 20) remained drop-free with continued IOP reductions > 20% across all remaining subjects. Each treatment arm realized mean IOP reductions from 32.3% to 49.3% over 3 years of follow-up visits. There were no significant intergroup differences. All eyes had a final best-corrected distance visual acuity of 20/30 or better. There were no serious implant-related adverse events. The most common events were dry eye (21.7%), transient vision decrease (13.0%), and subconjunctival hemorrhage (8.7%). All implants remained in the capsular bag.

CONCLUSIONS:

The first human study of a novel system that mounts bimatoprost-infused pads to a single-piece IOL suggests favorable safety and efficacy and does not require additional surgical skills beyond routine cataract surgery. A larger sample with comparative data is necessary to further assess effects.

TRIAL REGISTRATION:

ClinicalTrials.gov identifiers, NCT07154797 and NCT07154810. Retrospectively registered on September 3, 2025.

01 Jan 2026·Indian Dermatology Online Journal

Vitamin D and its Analogs in Treatment of Mild to Moderate Alopecia Areata: Systematic Review and Meta-Analysis

Article

Author: Alzabadin, Rakan Abdullah ; Alzakry, Leena Mohammed ; Alsaadoun, Dalal ; Kaliyadan, Feroze ; Rubaian, Nouf F. Bin ; Hakami, Turki Hassan ; Alsaati, Ahmed Abdulaziz

Abstract:

Background::

Recently, vitamin D3 and its analogs have shown therapeutic potential in the treatment of alopecia areata (AA).

Aim and Objective::

The aim of this study was to evaluate the safety/efficacy of topical/intralesional vitamin D3 and its analogs for treatment of mild-to-moderate AA.

Materials and Methods::

We included clinical trials that evaluated topical/intralesional vitamin D3 and its analogs for the treatment of AA. Response rates were defined as either achieving a Score 4 (S4) response on the hair regrowth scale (≥75% regrowth) or reduction in the mean Severity of Alopecia Tool (SALT) score after treatment.

Results::

The overall success rate of vitamin D3 and its analogs in the treatment of mild-to-moderate AA is about 53.75%. Both intralesional and topical vitamin D3 (odds ratio = 3.20; 95% confidence interval (CI): [1.24, 8.24] and mean difference (MD) = 2.11; 95% CI: [-1.10, 5.31], respectively) are effective in the treatment of mild-to-moderate AA. Additionally, topical vitamin D3 analogs had a synergistic effect when used in combination with other treatments including topical corticosteroids and NB-UVB (MD = 0.62; 95% CI: [-0.24, 1.48] and MD = 1.34; 95% CI: [0.96, 1.71]), respectively. Intralesional vitamin D3 showed lower efficacy compared to intralesional corticosteroid and topical bimatoprost (MD = -4.73; 95% CI: [-7.38, -2.08]). No serious adverse events were associated with the use of vitamin D3 and its analogs.

Limitations::

Small number of randomized clinical trials, lack of baseline vitamin D3 levels and co-morbid autoimmune conditions assessment.

Conclusion::

Vitamin D3 and its analogs may serve as a safe, inexpensive alternative for mild-to-moderate patchy AA, either as a mono-therapeutic agent or as an adjuvant for more severe cases.

144

News (Medical) associated with Bimatoprost

30 Apr 2026

·www.biospace.com

Nicox Provides Full Year 2025 Financial Results and Corporate Update

Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024) NCX 470 U.S. New Drug Application (NDA) submission on track for summer 2026, with associated milestone payment Regulatory milestones anticipated to extend cash runway beyond 2027 April 30, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced its financial results for the full year of 2025, as approved by the Board of Directors on 29 April 2026, and provided an update on key future milestones. “2025 marked a pivotal turning point for Nicox,” said Gavin Spencer, Chief Executive Officer of Nicox. “We have significantly strengthened our financial position, reduced our net loss and eliminated secured debt, removing a number of long-term obligations on the Company. Our priorities are clear for 2026: supporting the submissions of the NCX 470 New Drug Applications in the U.S. and China along with our partners, which are expected to facilitate a new future long-term revenue stream for the company, and on exploring strategic opportunities to maximise our value . ” Key Future Milestones NCX 470 NDA submission in the United States: expected summer 2026. NCX 470 NDA submission in China: expected shortly after submission in the U.S. NCX 470 Phase 3 clinical program in Japan: initiated summer 2025. Full Year 2025 Financial Results for Nicox SA The Financial Statements for 2025 are provided in the appendix to this Press Release. Revenue for the full year of 2025 was €16.8 million versus €7.9 million for the full year 2024, principally consisting of milestone payments from Kowa related to the NCX 470 license agreements outside China and Southeast Asia. The revenue for 2025 also includes €1.2 million of intercompany billings compared to €0.2 million for 2024. Revenue in 2024 included €3.0 million of VYZULTA royalties, recognized up to 30 June 2024 prior to their sale to Soleus Capital; a €3.0 million upfront payment from Kowa for the Japanese rights to NCX 470 and a non-cash amount of €1.5 million previously recognized as deferred income. Operating expenses for the full year 2025 were €14.3 million compared to €18.7 million for the full year 2024, reflecting the completion of the second pivotal Phase 3 trial (Denali) for NCX 470, with initial results released in August 2025. No exceptional income was recognized in 2025 compared to €13.7 million recorded in 2024 following the sale of the future milestones and royalty of VYZULTA to Soleus Capital. Nicox recorded a net loss of €2.4 million in 2025, compared to a net loss of €22.4 million in 2024, reflecting a significant improvement driven by higher revenues, primarily from milestone payments, and lower operating expenses following the completion of the Phase 3 Denali trial for NCX 470. As of 31 December 2025, Nicox had cash and cash equivalents of €4.1 million compared to €10.5 million as of 31 December 2024. Including the regulatory milestone payments expected for NCX 470 and assuming a standard 12-month review period after the NDA filing, the Company estimates it is funded beyond 2027. The Company remains committed to cost control and optimizing resource allocation to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway. The Company is pursuing business development discussions and continuing to evaluate a number of strategic growth opportunities, including collaborations or business combinations. Potential proceeds from existing warrants are not included in the above cash runway calculation. Details of the warrants from the June 2024 financing are given in our Q&A section of . Post-reporting period events The remaining €1.0 million from the financing announced in our Press Release of January 5, 2026, has just been released. As previously anticipated, the Company has decided, with the holders’ agreement, to convert the ordinary bonds established in January 2026 into convertible bonds (OCs) of the same nature and with the same characteristics as the OCs issued in January 2026, and to which they have been assimilated 1 . The ordinary bonds were converted into OCs pursuant to the decision of the Board of Directors taken at its meeting of 29 April 2026. About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information Analyst coverage H.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com Disclaimer The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “ Rapport Annuel 2025 ” which are available on Nicox’s website ( ). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail. Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 Income Statement (in thousands of euros) December 31, 2025 December 31, 2024 Net sales (revenue) 16,771 7,859 Reversals of depreciation, impairment and provisions 2,000 444 Proceeds from disposals of intangible and tangible fixed assets 1 - Other income 176 574 OPERATING INCOME 18,948 8,877 Other purchases and external expenses (10,233) (14,552) Taxes, duties and similar payments (other than on income) (44) (72) Salaries (1,220) (2,092) Social charges (580) (651) Depreciation and impairment of intangible and tangible fixed assets (10) (17) Provision expense (44) (12) Net book value of disposed intangible and tangible fixed assets (2,003) - Other expenses (188) (1,335) OPERATING EXPENSES (14,322) (18,731) OPERATING PROFIT (LOSS) 4,626 (9,854) Income from equity investments - 3,050 Income from other long-term securities and receivables 240 244 Other interest and similar income 506 601 Reversals of impairment and provisions 16,152 13 Foreign exchange gains 47 371 FINANCIAL INCOME 16,945 4,279 Amortization, depreciation and financial provisions (20,363) (27,776) Interest and similar expenses (2,950) (1,557) Foreign exchange loss (671) (45) FINANCIAL EXPENSES (23,984) (29,378) FINANCIAL PROFIT (LOSS) (7,039) (25,099) PRE-TAX INCOME (LOSS) (2,413) (34,952) Exceptional income on management operations - 13,743 Exceptional income on capital operations - 3 EXCEPTIONAL INCOME - 13,746 Exceptional charges on management operations - (2) Exceptional charges on capital operations - (922) EXCEPTIONAL EXPENSES - (924) EXCEPTIONAL INCOME (LOSS) - 12,822 Research Tax Credit - (259) NET PROFIT & LOSS (2,413) (22,390) Balance sheet (in thousands of euros) December 31, 2025 December 31, 2024 ASSETS Intangible assets 6 13 Property, plant and equipment 5 11 Financial assets 139 725 TOTAL FIXED ASSETS 150 749 Trade receivables and related accounts 936 1,643 Other receivables 2,268 9,349 Prepaid expenses 1,280 1,515 Cash and cash equivalents 4,147 10,542 TOTAL CURRENT ASSETS 8,631 23,049 Unrealized foreign exchange losses and valuation differences - Assets 1,592 13 Bond redemption premiums - 610 TOTAL REGULARISATION ACCOUNTS 1,592 623 TOTAL ASSETS 10,373 24,421 LIABILITIES Issued Capital 884 692 Share premium 538,377 533,549 Retained earnings (530,828) (508,438) Net loss for the period (2,413) (22,390) TOTAL SHAREHOLDERS' EQUITY 6,020 3,413 Provisions for liabilities 1,591 13 Provisions for charges 312 268 TOTAL PROVISIONS FOR LIABILITIES AND CHARGES 1,903 281 Loans and debts from lending institutions 337 15,064 Loans and other financial debts 67 82 Accounts payable and related accounts 675 1,651 Tax and social security liabilities 751 603 Deferred income 617 735 TOTAL LIABILITIES 2,447 18,135 Unrealized foreign exchange gains and valuation differences - Liabilities 3 2,592 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 10,373 24,421 1 For illustrative purposes, if all the convertible bonds announced today were converted based on the Nicox share price at the close market on April 29, 2026 and of outstanding shares as of April 29, 2026, a shareholder holding 1.00% of Nicox's share capital prior to the transaction would see their holding reduced to 0.97% of the share capital on a non-diluted basis and to 0.74% on a fully diluted basis (taking into account existing dilutive instruments). Attachment EN_FY2025_PR_FINAL

Financial StatementPhase 3License out/in

20 Apr 2026

·www.globenewswire.com

Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026

Press Release Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026April 20, 2026 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today reminds holders of the warrants issued in June 2024 as part of the Company’s equity offering with preemptive rights that these warrants will expire on June 20, 2026. June 20 being a Saturday, the last effective date for trading or exercising the warrants will be Friday, June 19, 2026, close of market day.Reminder of the main features of the warrants Listing of the warrants: The warrants are listed on Euronext Growth ParisISIN code: FR001400QEQ3Exercise period: from June 21, 2024 to June 19, 2026 (close of market)Exercise parity: 5 warrants give the holder the right to subscribe to 2 new Nicox sharesExercise price: €0.275 per new share Any warrants not exercised by the close of market day on Friday, June 19, 2026 will automatically expire, will no longer be exercisable and will no longer have any value. As of March 31, 2026, 10,022,595 June 2024 warrants remain outstanding and exercisable, representing a potential issuance of 4,009,038 new shares upon exercise. For illustrative purposes, if all outstanding June 2024 warrants were exercised, a shareholder holding 1% of the capital (calculated on the basis of the number of outstanding shares as of March 31, 2026) prior to the exercise of the outstanding warrants would hold 0.96% of the capital on a non-diluted basis and 0.75% on a fully diluted basis. Exercise procedureTo exercise their warrants, holders should contact the financial intermediary holding their securities account (bank or broker). Details of the warrants from the June 2024 financing are given in the Q&A section of our website: www.nicox.com.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.comDisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” and in section 4 of the “Rapport semestriel 2025” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_WarrantsReminder_FINAL

09 Apr 2026

·www.biospace.com

Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

Important ophthalmic treatment expected to be an important growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN ® (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. “We are pleased to bring another key ophthalmic therapy to our Affordable Medicines portfolio,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “As glaucoma prevalence continues to rise, particularly among the aging population, expanding access to effective treatments like bimatoprost is critical. This launch builds on our strong cadence of complex product introductions and represents an important growth driver for our Affordable Medicines segment.” The most common adverse reaction associated with bimatoprost ophthalmic solution 0.01% is conjunctival hyperemia. For prescribing information, see package insert here . According to IQVIA ® U.S. annual sales for bimatoprost ophthalmic solution 0.01% for the 12 months ended February 2026 were approximately $719 million. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more, please visit and follow us on LinkedIn . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof. Investor Contact Anthony DiMeo VP, Investor Relations anthony.dimeo@amneal.com Media Contact Brandon Skop Sr. Director, Corporate Communications brandon.skop@amneal.com

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 3	United States	SpyGlass Pharma, Inc.	15 Oct 2025
Hydrophthalmos	Phase 3	United States	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	France	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Italy	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Philippines	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	South Korea	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Taiwan Province	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	United Kingdom	Allergan UC	01 Sep 2011
Alopecia	Phase 3	Japan	Allergan UC	01 Jul 2011
Androgenetic Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06120842 (Tigris, GlobeNewswire) Manual	Phase 1/2	Ocular Hypertension	-	Bimatoprost	kdiwvrcwfx(chjmduszlm) = lfiolibrts hxsnnwqswg (ftfnijqjlt ) View more	Positive	14 Oct 2025
FDA_CDER Manual	Not Applicable	Glaucoma, Open-Angle \| Ocular Hypertension	-	0.01% ZOLYMBUS	ieedrgdjgn(wkpqiznjmh) = OLYMBUS once daily (in the evening) was non-inferior to preserved bimatoprost ophthalmic solution 0.01%. jxdmwrwhwt (grlspjldbh ) View more	Positive	09 Sep 2025
				0.01% preserved bimatoprost ophthalmic solution
NCT03891446 (MAIA, ARVO2025)	Phase 3	Glaucoma, Open-Angle \| Ocular Hypertension	75	1 administration of 10 μg Intracameral Bimatoprost	iyymrngyuq(xxwcpphexo) = hepemxnwrn utdghadvzw (reiywhprxp, 1.23)	Positive	04 May 2025
				2 administrations of 10 μg Intracameral Bimatoprost	iyymrngyuq(xxwcpphexo) = tainzebhtr utdghadvzw (reiywhprxp, 1.45)
NCT03850782 (TRITON, Pubmed \| Drugs)	Phase 3	Ocular Hypotension	441	Bimatoprost implant 10 µg	dmnysmgbgp(iigazfndmv) = xpnmendyxy osxhocphto (jdoiczxbfb, 369 - 485) View more	Positive	01 Apr 2025
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1LL-BMT1 32-µg dose	qsxbljyszq(xpgzfkrayk) = stptyswtmh aiwtmjxuxc (nhvtdivvvz ) View more	Positive	12 Nov 2024
				bimatoprostbimatoprost 0.01%	-
NCT02507687 (CTgov)	Phase 3	Glaucoma, Open-Angle	240	SLT (Stage 2: SLT)	yszgtienns(hexjswkgjh) = ipnynxvndl jzvvyrzcss (bqlireexnj, 0.28) View more	-	10 May 2024
				Bimatoprost SR (Stage 2: Bimatoprost SR 10 µg)	yszgtienns(hexjswkgjh) = krganqmkot jzvvyrzcss (bqlireexnj, 0.28) View more
NCT03850782 (ARVO2024)	Phase 3	Glaucoma, Open-Angle \| Ocular Hypertension	423	Bimatoprost implant (Open-angle glaucoma or Ocular hypertension)	lbkpylwjdd(slvvlryibo) = gfrfvklgip ginlsqdedc (fmhcanebjt ) View more	Positive	05 May 2024
ARVO2024	Not Applicable	Ocular Hypertension \| Glaucoma, Open-Angle	792	Bimatoprost SR implant	tuzvzqmhvc(wcdvlmdswe) = qiecxktynq vtgujkiwbz (xqnekkjmhj )	Positive	05 May 2024
NCT03825380 (CTgov)	Phase 3	Glaucoma, Open-Angle \| Glaucoma	485	Bimatoprost (T4032)	klqvyrfsep(wxiekbfbrq) = dxflruwjct jgcuvyqqaz (vhpufrwian, 0.19) View more	-	21 Nov 2023
				Lumigan® (Lumigan®)	klqvyrfsep(wxiekbfbrq) = grmtnebsnu jgcuvyqqaz (vhpufrwian, 0.18) View more
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	nsrenqeqzs(vrwuddxzch) = yhxdprflzu zeijozeoxr (iampougqgp, 5.65) View more	-	08 Jun 2023
				LUMIGAN (LUMIGAN 0.01%)	nsrenqeqzs(vrwuddxzch) = ziixjriduc zeijozeoxr (iampougqgp, 5.27) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis